BBIO vs. DHR: BridgeBio Pharma vs. Danaher Stock Comparison

November 11, 2026

How do BridgeBio Pharma (BBIO) and Danaher (DHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BridgeBio Pharma (BBIO) and Danaher (DHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while DHR is classified in Life Sciences Tools & Services.

Company profile comparison for BridgeBio Pharma (BBIO) and Danaher (DHR)
Profile Item	BBIO	DHR
Name	BridgeBio Pharma Inc.	Danaher Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	14.47 billion USD	161.86 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 27, 2019	December 29, 1978
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BBIO

DHR

GSPC

BridgeBio Pharma (BBIO) vs. Danaher (DHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BridgeBio Pharma (BBIO) and Danaher (DHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BridgeBio Pharma (BBIO) and Danaher (DHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
Total Return (1Y)	22.70%	11.88%
Total Return (3Y, Annualized)	40.97%	6.67%
Total Return (5Y, Annualized)	8.25%	-2.05%

Risk Profile

Drawdown History

BBIO

DHR

GSPC

BridgeBio Pharma (BBIO) vs. Danaher (DHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BridgeBio Pharma (BBIO) and Danaher (DHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
Volatility (1Y, Annualized)	44.39%	30.61%
Beta (5Y)	0.93	0.76
Max Drawdown (5Y)	-89.79%	-43.31%
Avg. Volume (3M)	2.68M	3.94M

Risk-Adjusted Performance

Risk-Return Positioning

BBIO and DHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
Sharpe Ratio (1Y)	0.41	0.25
Sortino Ratio (1Y)	0.63	0.35

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Danaher (DHR) earns 8.19% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
BBIO: --

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 109.18%
DHR: 8.19%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

BridgeBio Pharma (BBIO) vs. Danaher (DHR): BBIO does not report ROE, so it has no value marker; DHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Danaher (DHR) reports 16.91%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
BBIO: -59.84%

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max: 18.05%
DHR: 16.91%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Danaher (DHR) reports 21.13%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
BBIO: -3.30%
Q1: -78.82%
Min: -207.40%

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max: 83.12%
DHR: 21.13%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
ROE (TTM)	--	8.19%
ROA (TTM)	-13.97%	4.06%
Net Margin (TTM)	-59.84%	16.91%
Operating Margin (TTM)	-3.30%	21.13%
Gross Margin (TTM)	94.34%	59.36%

Growth

Revenue Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Danaher (DHR) at 2.90% is closer to the peer norm — faster top-line expansion for BBIO.

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Danaher (DHR) reports EPS growth of -4.54%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
Revenue Growth (YoY)	126.26%	2.90%
Revenue Growth (3Y CAGR)	86.30%	-2.67%
EPS Growth (YoY)	--	-4.54%
EPS Growth (3Y CAGR)	--	-19.44%

Financial Strength

Current Ratio (MRQ)

Both BridgeBio Pharma (BBIO) at 2.09 and Danaher (DHR) at 1.63 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BBIO: 2.09
Min: 0.10

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
DHR: 1.63
Min: 0.10

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Danaher (DHR) carries debt-to-equity ratio of 0.52 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
BBIO: --

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max: 1.42
Q3: 0.65
DHR: 0.52
Median: 0.15
Q1: 0.02
Min: 0.00

BridgeBio Pharma (BBIO) vs. Danaher (DHR): BBIO does not report debt-to-equity ratio, so it has no value marker; DHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
Current Ratio (MRQ)	2.09	1.63
Debt / Equity (MRQ)	--	0.52
Net Debt / EBITDA	--	2.68

Dividends

Dividend Yield (TTM)

BridgeBio Pharma (BBIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR: 0.67%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

BridgeBio Pharma (BBIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR: 25.17%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
Dividend Yield (TTM)	0.00%	0.67%
Dividend Payout Ratio (TTM)	0.00%	25.17%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Danaher (DHR) trades at 38.12 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BBIO: --

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max: 85.34
Q3: 43.46
DHR: 38.12
Median: 26.69
Q1: 13.30
Min: 0.07

BridgeBio Pharma (BBIO) vs. Danaher (DHR): BBIO does not report P/E ratio, so it has no value marker; DHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Danaher (DHR) at 6.32 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max: 58.18
Q3: 25.77
BBIO: 15.31
Median: 7.30
Q1: 3.01
Min: 0.01

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max: 58.18
Q3: 25.77
Median: 7.30
DHR: 6.32
Q1: 3.01
Min: 0.01

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Danaher (DHR) reports 3.02, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BBIO: -5.59
Min: -5.59

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max: 13.53
Q3: 6.54
Median: 3.25
DHR: 3.02
Q1: 1.69
Min: -5.59

BridgeBio Pharma (BBIO) vs. Danaher (DHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BridgeBio Pharma (BBIO) and Danaher (DHR)
Metric	BBIO	DHR
P/E Ratio (TTM)	--	38.12
P/S Ratio (TTM)	15.31	6.32
P/B Ratio (MRQ)	-5.59	3.02
Free Cash Flow Yield (TTM)	-1.98%	2.93%